Patents by Inventor Allison Marlow

Allison Marlow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070299063
    Abstract: Disclosed are amino acid prodrugs of compounds of the formula I and pharmaceutically acceptable salts thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: June 14, 2007
    Publication date: December 27, 2007
    Applicant: Array BioPharma, Inc.
    Inventors: Eli Wallace, Joseph Lyssikatos, Allison Marlow, T. Hurley, Kevin Koch
  • Publication number: 20070238726
    Abstract: Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: March 6, 2007
    Publication date: October 11, 2007
    Inventors: James Blake, Steven Boyd, Jason De Meese, Kin Fong, John Gaudino, Tomas Kaplan, Allison Marlow, Jeongbeob Seo, Allen Thomas, Hongqi Tian, Frederick Cohen, Wendy Young
  • Publication number: 20070197537
    Abstract: Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: January 30, 2007
    Publication date: August 23, 2007
    Inventors: James Blake, Steven Boyd, Jason De Meese, John Gaudino, Allison Marlow, Jeongbeob Seo, Allen Thomas, Hongqi Tian
  • Publication number: 20070112038
    Abstract: Disclosed are compounds of the Formulas I and V and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 17, 2006
    Publication date: May 17, 2007
    Inventors: Allison Marlow, Eli Wallace, Jeongbeob Seo, Joseph Lyssikatos, Hong Yang, James Blake
  • Publication number: 20060106225
    Abstract: Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, t, R1, R2, R7, R9, R10, R11 and R12 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: October 25, 2005
    Publication date: May 18, 2006
    Inventors: Eli Wallace, Joseph Lyssikatos, Allison Marlow, T. Hurley
  • Publication number: 20060030610
    Abstract: Disclosed are methods of treating inflammatory diseases and disorders, such as arthritis and inflammatory bowel disease, in mammals.
    Type: Application
    Filed: August 19, 2005
    Publication date: February 9, 2006
    Inventors: Kevin Koch, T. Hurley, Hong Yang, Joseph Lyssikatos, James Blake, Allison Marlow, Eli Wallace
  • Publication number: 20050256123
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 18, 2005
    Publication date: November 17, 2005
    Inventors: Allison Marlow, Eli Wallace, Jeongbeob Seo, Joseph Lyssikatos, Hong Yang, James Blake
  • Publication number: 20050250782
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specifications. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: November 18, 2004
    Publication date: November 10, 2005
    Inventors: Allison Marlow, Eli Wallace, Jeongbeob Seo, Joseph Lyssikatos, Hong Yang, James Blake
  • Publication number: 20050153942
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X, Y and Z are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: November 18, 2004
    Publication date: July 14, 2005
    Inventors: Eli Wallace, Jeongbeob Seo, Joseph Lyssikatos, Hong Yang, T. Hurley, Allison Marlow, James Blake
  • Publication number: 20050143438
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 18, 2005
    Publication date: June 30, 2005
    Inventors: Eli Wallace, Joseph Lyssikatos, Allison Marlow, T. Hurley
  • Publication number: 20050054701
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9 and R10, W and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: August 30, 2004
    Publication date: March 10, 2005
    Inventors: Eli Wallace, Brian Hurley, Hong Yang, Joseph Lyssikatos, Jim Blake, Allison Marlow